United Therapeutics (UTHR) Tops Q2 EPS by 82c
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $508.48 +1.75%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.98, $0.82 better than the analyst estimate of $3.16. Revenue for the quarter came in at $444.5 million versus the consensus estimate of $368.58 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- United Therapeutics completes enrollment in PPF lung fibrosis trial
- XP Inc. (XP) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
